Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence-Free Survival in Hepatocellular Carcinoma Patients With High-Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study

Hanchuan Shen; Bing Liu; Hangyu Zhang; Yang Liu; Chenggang Li

doi:10.1002/mog2.70013

MEDCOMM - Oncology ›› 2025, Vol. 4 ›› Issue (1) : e70013 DOI: 10.1002/mog2.70013

LETTER

Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence-Free Survival in Hepatocellular Carcinoma Patients With High-Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study

Author information +

History +

PDF

Cite this article

Download citation ▾

Hanchuan Shen, Bing Liu, Hangyu Zhang, Yang Liu, Chenggang Li. Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence-Free Survival in Hepatocellular Carcinoma Patients With High-Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study. MEDCOMM - Oncology, 2025, 4(1): e70013 DOI:10.1002/mog2.70013

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	L. Q.Yao, Z. L.Chen, Z. H.Feng, et al., “Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients With Recurrence: A Multi-Institutional Analysis,” Annals of Surgical Oncology 29, no. 7 (2022):4291–4303.

[2]

A.Yopp, M.Kudo, M.Chen, et al., “LBA39 Updated Efficacy and Safety Data From IMbrave050: Phase III Study of Adjuvant Atezolizumab (Atezo) +Bevacizumab (Bev) vs Active Surveillance in Patients (Pts) With Resected or Ablated High-Risk Hepatocellular Carcinoma (HCC),” supplement, Annals of Oncology 35, no. S4 (2024): S1230.

[3]	H.Li, J.Wang, G.Zhang, et al., “Transarterial Chemoembolization Combined Donafenib With/Without PD-1 for Unresectable HCC in a Multicenter Retrospective Study,” Frontiers in Immunology 14 (2023):1277329.

[4]	H.Lu, B.Liang, X.Xia, and C. Zheng, “Efficacy and Safety Analysis of TACE+Donafenib+Toripalimab Versus TACE+Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study,” BMC Cancer 23, no. 1 (2023):1033.

[5]	J.Sun, R.Guo, X.Bi, et al., “Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus in China (2021 Edition),” Liver Cancer 11, no. 4 (2022):315–328.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).